The World Market for Diabetes Treatments
Price (Single User PDF): $2,995.00
Price (Global Site License): $5,990.00
This Kalorama Information report , The World Market for Diabetes Treatments, provides market estimates and forecasts for the world market for diabetes treatments. The diabetes market is one of the fastest growing markets within the pharmaceutical sector, and is one of the few pharmaceutical sectors that are likely to continue to grow at double digit rates throughout the forecast period. Major contributing factors to growth are increasing obesity and an aging worldwide population. The total market for diabetes treatments is divided into two major segments:
The report’s geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:
Price (Global Site License): $5,990.00
This Kalorama Information report , The World Market for Diabetes Treatments, provides market estimates and forecasts for the world market for diabetes treatments. The diabetes market is one of the fastest growing markets within the pharmaceutical sector, and is one of the few pharmaceutical sectors that are likely to continue to grow at double digit rates throughout the forecast period. Major contributing factors to growth are increasing obesity and an aging worldwide population. The total market for diabetes treatments is divided into two major segments:
- Insulin Markets in US, Europe, Japan, ROW
- Oral Hypoglycemics in US, Europe, Japan, ROW
The report’s geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:
- New Products and the Development Pipeline (Afrezza, Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna Otelixizumab and others)
- Transplantation Research Efforts
- Β-Cell Transplantation Research
- Potential New Drug for Type 2 Diabetes
- Insulin Pills
- Three-month Insulin Shot
- Outsourcing of Diabetes Projects
- Reclassification of Cause of Death
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Eli Lilly & Co.
- Merck
- Metabolex, Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi-Aventis Group
- Takeda Pharmaceutical Company Limited
- CHAPTER ONE: EXECUTIVE SUMMARY
- Background
- Scope and Methodology
- Size and Growth of the Market
- Key Issues and Trends Affecting Market
- Leading Competitors
- CHAPTER TWO: INTRODUCTION
- Background
- Therapeutic Practices
- France
- Germany
- Italy
- Japan
- Spain
- United Kingdom
- United States
- China
- India
- CHAPTER THREE: CURRENT THERAPEUTICS FOR DIABETES
- Insulin
- Regular Insulin
- Long-Acting and Basal Insulin
- Rapidly Acting Insulin
- Combinations
- Insulin Pumps
- Insulin Pens
- Inhaled Insulin
- Other Treatments
- Oral Hypoglycemics
- Sulfonylureas Biguanides
- a-Glucosidase Inhibitors
- Thiazolidinediones
- Meglitinides
- D-Phenylalanine Derivatives
- GLP1 Agonists
- DPP-IV Inhibitor
- Current Therapeutics for Diabetic Complications
- Antihypertensive Therapy
- ACE Inhibitors
- a/a(Alpha/Beta)-Blockers
- Calcium Channel Blockers
- Diuretics
- Angiotensin II Receptor Antagonists
- Dyslipidemia Therapy
- HMG-CoA Reductase Inhibitors--Statins
- Bile Acid Sequestrants
- Fibric Acid Derivatives
- Niacin
- Cholesterol Absorption Inhibitors
- Atherosclerosis Therapy
- Arrhythmia Therapy
- Peripheral Vascular Disease Therapy
- CHAPTER THREE: TOTAL MARKET REVENUES, FORECAST AND COMPETITIVE ANALYSIS
- Total Worldwide Diabetes Market Analysis by Geographic Segment
- Total Worldwide Diabetes Market Competitive Analysis
- Total Worldwide Diabetes Market by Segment
- Insulin
- Oral Hypoglycemics
- CHAPTER FOUR: KEY ISSUES, TRENDS AND DEVELOPMENTS
- New Products and the Development Pipeline
- Afrezza
- Bydureon
- Syncria
- AVE0010 Once Daily and Twice Daily
- Balaglitazone
- Dapagliflozin and Dapagliflozin/Meformin Fixed Dose Combination
- Degludec and Degludec Plus
- Daimyd Vaccine
- Dutogliptin
- Glinsuma, Glufast, Metgluna
- MK 0431C
- Ondero
- Oral-lyn
- Otelixizumab
- Taspoglutide
- Transplantation Research Efforts
- A-Cell Transplantation Research
- Potential New Drug for Type 2 Diabetes
- Insulin Pills
- Three-month Insulin Shot
- Outsourcing of Diabetes Projects
- Reclassification of Cause of Death
- CHAPTER FIVE: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TO THE TREATMENT OF DIABETES
- Background
- Nutritional Supplements
- Ascorbic Acid (Vitamin C)
- Biotin
- Chromium
- Copper
- Magnesium
- Niacin and Niacinamide
- Potassium
- Selenium
- Thiamine
- Vanadium
- Vitamin B6 (Pyridoxine)
- Vitamin B12
- Vitamin E
- Zinc
- Nutritional Treatment of Diabetic Neuropathy
- Herbal Treatment of Diabetes
- Aloe (Various)
- Arctium lappa (Burdock Root)
- Allium cepa (Onion)
- Grifola frondosa (Maitake Mushroom)
- Mulberry
- Panax ginseng (Korean ginseng)
- Ayurvedic Medicine and Herbs
- Gymnema sylvestre (Asclepias germinata)
- Momordica charantia (Bitter Gourd)
- Trigonella foenum graecum (Fenugreek)
- Other Herbs with Significant Anti-Diabetic Effects
- Traditional Chinese Medicine
- CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Implications:
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
- Seventh Conclusion
- Implications:
- Eighth Conclusion
- Implications:
- Ninth Conclusion
- Implications:
- Tenth Conclusion
- Implications:
- Eleventh Conclusion
- Implications:
- Twelfth Conclusion
- Implications:
- Thirteenth Conclusion
- Implications:
- Fourteenth Conclusion
- Implications:
- Fifteenth Conclusion
- Implications:
- CHAPTER SEVEN: LEADING MANUFACTURERS
- Overview
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Eli Lilly & Co.
- Merck
- Metabolex, Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi-Aventis Group
- Takeda Pharmaceutical Company Limited
- APPENDIX A: GLOSSARY
- APPENDIX B: COMPANY DIRECTORY